Pharma Facebook Pages Open To Comments

From today (August 15th), most pharmaceutical company pages on Facebook are due to be open to comments for the first time, something which could strain the industry’s difficult relationship with social media.

Many pharmaceutical companies only agreed to set up on Facebook in return for the ability to moderate and block comments on their pages, a privilege which was not accorded companies in other industries. The social media platform says it will however still allow comment disabling on some branded pages that refer to a specific drug.

Some drug makers – including AstraZeneca and Johnson & Johnson – say they have decided to remove pages as a consequence of the policy change, according to a Washington Post article.  Pharma has always been wary of social media because of stringent rules governing the information it can impart to consumers, and has been much slower than other sectors in embracing social media platforms.

Drug makers say they are concerned that commenters may reference side effects or proffer medical advice, or mention brands without ‘fair balance’, although critics of the stance argue their reluctance stems more from a lack of understanding about social media and fears about loss of control.

The industry has also said it lacks clear guidance from regulatory authorities on what it can and cannot communicate via social media. The US FDA has not yet released its own guidelines although it has suggested they may be completed before the end of this year.

For its part, Facebook now maintains that as a social media platform it is interactive by definition, and restricting comments undermines the entire purpose of the platform.  The message is that comment-free pages are essentially advertising, not social interaction, and the change in policy is necessary to encourage dialogue between drug makers and their customers.


Industry News, Social Media